Concert Pharmaceuticals, a small biotechnology company based in Lexington, Massachusetts, plans to seek Food and Drug Administration approval for its experimental hair loss drug after reporting success in the second of two late-stage clinical trials.
As in the first study, results from the second showed Concert’s treatment helped regrow hair to a significantly greater degree than a placebo, the company said in a Monday statement. The study also met its secondary goal assessing participant satisfaction with their hair growth.
